Vasomotor symptoms (VMS), including hot flashes and night sweats, are among the most common and distressing experiences reported by menopausal women. These symptoms significantly impact quality of life and daily functioning. A promising treatment, Bayer’s elinzanetant, designed to address moderate to severe VMS, is currently under review by the U.S. Food and Drug Administration (FDA). However, the agency has recently announced an extension of its review period for this new drug application (NDA).
The FDA’s Decision
On July 25, 2025, Bayer revealed that the FDA required additional time to review the NDA submission for elinzanetant. This extension, spanning up to 90 days, aims to allow the agency to thoroughly assess the comprehensive data provided in the application, including results from three pivotal Phase 3 clinical trials. Despite the delay, Bayer stated that the FDA had not raised concerns regarding the drug’s general approvability.
Clinical Data Supporting Elinzanetant
The NDA for elinzanetant is supported by robust data from three Phase 3 studies—OASIS 1, OASIS 2, and OASIS 3. These trials evaluated the safety and efficacy of elinzanetant compared to a placebo, focusing on its capacity to alleviate moderate to severe VMS. Positive results from these studies underscore the drug’s potential as a novel therapeutic option for menopause-related symptoms.
Expert Insights
Dr. Christian Rommel, PhD, member of Bayer’s Pharmaceuticals Division and Global Head of Research and Development, emphasized the significance of the Phase 3 findings: “The consistent positive results from our clinical program reinforce our confidence in elinzanetant’s potential. We are committed to ensuring the availability of this treatment option for women in the U.S. following FDA approval.”
Global Approval Status
Elinzanetant has already gained approval in the United Kingdom and Canada, marketed under the brand name Lynkuet, for the treatment of mild to moderate VMS. These approvals highlight its international recognition and potential for broader adoption.
Case Scenario: Mary’s Experience
Mary, a 52-year-old teacher, has been struggling with intense hot flashes and disrupted sleep due to night sweats for over a year. Traditional therapies offered limited relief, prompting her to explore new options. With the anticipated approval of elinzanetant in the U.S., Mary is hopeful for a treatment tailored to her needs, improving her quality of life.
Conclusion
While the FDA’s extended review period for elinzanetant may delay its availability, the thorough evaluation process ensures that patients receive safe and effective treatments. Bayer remains optimistic about the drug’s approval and its potential to transform menopause care. Women experiencing VMS can look forward to innovative solutions that address their unique challenges.
Reference
Bayer. Bayer provides regulatory update on elinzanetant in the U.S. Bayer provides regulatory update on elinzanetant in the U.S. Bayer. July 25, 2025. Accessed July 25, 2025. https://www.bayer.com/media/en-us/bayer-provides-regulatory-update-on-elinzanetant-in-the-us/
